Projet Sen B: Gratuité Traitement Hépatite B Sénégal Faces Funding Challenge

• Projet Sen B, launched in 2019, provides free comprehensive care for over 1,000 Hepatitis B patients in Senegal.
• The project's operations, including patient follow-up costing up to 300,000 FCFA per patient, are heavily reliant on external funding.
• Current annual funding of approximately 200,000 euros for follow-up is deemed insufficient, necessitating new financial support.
• Despite subsidies, the antiviral drug Tenofovir costs about 5,000 FCFA per box, creating a significant financial barrier for patients.
• The National Hepatitis Control Program advocates for free Hepatitis B treatment in Senegal, similar to HIV/AIDS care, to ensure equitable access to medication.

This expense poses a substantial financial burden for patients who require long-term treatment, raising critical questions about equity in healthcare access.

The Projet Sen B, initiated in 2019, stands as a crucial research and care framework designed to deepen the understanding of Hepatitis B and enhance therapeutic interventions within Senegal. Professor Moussa Seydi from the Fann University Hospital Center underscores the project's significance, noting its broad scope encompassing fundamental research, clinical patient management, treatment efficacy evaluation, prevention of mother-to-child transmission, social sciences, and economic analysis. This multi-dimensional effort has yielded tangible benefits for the population, with over 1,000 individuals receiving complimentary care. This extensive support includes consultations, semi-annual ultrasounds, biological examinations, viral load measurements, and, for some patients, necessary treatments or surgical procedures.

Despite these vital services, the financial demands of providing such comprehensive care are substantial. The cost for patient follow-up can reach up to 300,000 FCFA per individual, varying based on the specific examinations and treatments required. This considerable expense highlights the inherent fragility of a system heavily reliant on external funding and the dedicated commitment of medical and scientific teams. The sustainability of Projet Sen B's impact hinges on addressing these financial challenges to ensure continued access to critical care and research for Hepatitis B in Sénégal.

A primary challenge confronting Projet Sen B is its dependence on external partners for financial support. Since its inception, funding has primarily originated from Swiss collaborators, various research foundations, and American university partners, with additional contributions from industry partnerships covering specific laboratory tests. Professor Gilles Vandler, an infectious disease specialist at the University of Bern, has emphasized the critical need to secure long-term support and identify new funding streams to ensure the project's continuity.

The initiative currently mobilizes a diverse team of medical professionals, biologists, radiologists, and social science researchers dedicated to monitoring a cohort of over 1,000 individuals. However, the available funding, estimated at approximately 200,000 euros annually for the follow-up mechanism, is considered insufficient given the extensive needs. Professor Vandler stressed that securing additional financing is essential, as the continuation of high-quality research is directly linked to the partners' ability to maintain and strengthen their support. The project also aims to leverage accumulated data to better understand the epidemic's evolution in Senegal and develop projections based on access to treatments and prevention services, with future work focusing on improving clinical management, expanding scientific knowledge, and training new researchers.

Beyond the immediate funding requirements for research, the accessibility and cost of medication represent a significant hurdle in the fight against Hepatitis B in Sénégal. Bamba Kane, the coordinator of the Programme national lutte hépatites Sénégal, has highlighted the inadequacy of current resources allocated to combat this public health challenge. A particular concern is the cost of Tenofovir, a key antiviral medication used in Hepatitis B treatment. Despite being subsidized, the drug is not provided free of charge, with a single box costing approximately 5,000 FCFA.

This expense poses a substantial financial burden for patients who require long-term treatment, raising critical questions about equity in healthcare access. In response, Kane has strongly advocated for the implementation of free treatment for Hepatitis B, drawing a parallel to existing care models for other infectious diseases, such as HIV/AIDS. This call for `gratuité traitement hépatite B Sénégal` underscores the urgent need for policy changes to ensure that financial constraints do not impede access to life-saving medications, thereby improving `santé publique Sénégal hépatite B` outcomes and ensuring equitable `Sénégal hépatite B accès médicaments`.

Lawyers advising pharmaceutical companies, healthcare providers, or NGOs in Senegal should monitor ongoing advocacy for free access to Hepatitis B treatments, as this could lead to new public health policies, government subsidies, or changes in drug procurement regulations, impacting market access and compliance strategies.

Source: Original reporting via Senegalese press